Proteomics

Dataset Information

0

Exceptional Response to BTK Inhibitors in Aggressive Lymphomas Linked to Chronic Selective Autophagy


ABSTRACT: Diffuse large B cell lymphoma is an aggressive cancer type that is profoundly heterogeneous, both molecularly and phenotypically, presenting a challenge for precision medicine. Inhibitors of the kinase BTK block B cell receptor (BCR)-dependent NF-ï«B signaling and are particularly effective in certain molecular subtypes of DLBCL, but the underlying mechanisms are poorly understood. The MCD genetic subtype, which often acquires mutations targeting the BCR subunit CD79B and MYD88, typically resists chemotherapy but responds exceptionally to BTK inhibitors. By functional proteogenomics, we discovered a non-canonical form of chronic active selective autophagy in MCD DLBCL that targets ubiquitinated mutant MYD88, an adaptor protein essential for oncogenic NF-ï«B survival signaling, for degradation. Moreover, MCD tumors acquire genetic and epigenetic alterations that attenuate this novel tumor suppressive pathway. Importantly, BTK inhibitors activated this chronic selective autophagy pathway to degrade MYD88, thus explaining the exceptional benefit of BTK-targeted therapies in the MCD DLBCL subtype.

INSTRUMENT(S): Orbitrap Fusion, Orbitrap Exploris 480, Q Exactive HF, Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Cell Culture

DISEASE(S): Diffuse Large B-cell Lymphoma

SUBMITTER: Sebastian Scheich  

LAB HEAD: Louis M. Staudt

PROVIDER: PXD041092 | Pride | 2025-05-06

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
File_assignment.txt Txt
MQ_005.zip Other
MQ_011.zip Other
MQ_34-42.zip Other
MQ_441.zip Other
Items per page:
1 - 5 of 1164
altmetric image

Publications


Diffuse large B cell lymphoma (DLBCL) is an aggressive, profoundly heterogeneous cancer, presenting a challenge for precision medicine. Bruton's tyrosine kinase (BTK) inhibitors block B cell receptor (BCR) signaling and are particularly effective in certain molecular subtypes of DLBCL that rely on chronic active BCR signaling to promote oncogenic NF-κB. The MCD genetic subtype, which often acquires mutations in the BCR subunit, CD79B, and in the innate immune adapter, MYD88<sup>L265P</sup>, typi  ...[more]

Similar Datasets

2023-04-22 | PXD036363 | Pride
2018-05-01 | GSE99276 | GEO
2023-12-09 | PXD039012 | Pride
2016-05-09 | PXD003492 | Pride
2015-04-24 | PXD002098 | Pride
2018-12-14 | PXD009380 | Pride
2023-04-24 | PXD038951 | Pride
2022-01-24 | GSE171763 | GEO
2015-11-01 | E-GEOD-63029 | biostudies-arrayexpress
2020-12-07 | GSE141452 | GEO